

DAFTAR PUSTAKA

- Allredge, B. K., R.L. C., Ernst., B.j, G., Jacobson, P. A., & Kradjan, W.A., & Miller, J. H. (2012). *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*. 10th Ed. Philadelphia: Lippincott Williams & Wilkins.
- Amalia, M., Hidayati, P. H., Eka Yanti, A. K., Vitayani, S., & Gayatri, S. W. (2023). Karakteristik Pasien Sirosis Hepatis. *UMI Medical Journal*, 8(1), 53–61.
- Angeli, P., Labenz, C., Piano, S., Juanola, A., Krag, A., Caracen, P., Trebicka, J., Maiwall, R., Singh, V., Pose, E., Gambino, C., Marciano, S., Galle, P., Sarin, S., Ginès, P., & Kamath, P. (2025). Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus. *Journal of Hepatology*, 83(3), 800–802.
- Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. *Journal of Hepatology*, 70(1), 151–171.
- Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). *Goodman & Gilman's the pharmacological basis of therapeutics*. 13th Ed. New York: McGraw-Hill Education.
- Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2012). *Pharmacotherapy: A Pathophysiologic Approach*. 8th Ed. New York: McGraw-Hill Education.
- DiPiro, J. T., Wells, B. G., Schwinghammer, T. L., & DiPiro, C. V. (2021). *Pharmacotherapy: A Pathophysiologic Approach*. 11th Ed. New York: McGraw-Hill Education.
- European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *Journal of Hepatology*, 69(2), 23–30.
- Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018). Mechanisms of NAFLD development and therapeutic strategies. *Nature Medicine*, 24(7), 908–922.
- Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A., & Bosch, J. (2017). Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management. *Hepatology*, 65(1), 310–335.
- Hall, J. (2021). *Guyton and Hall Textbook of Medical Physiology* (14th ed.). Amsterdam: Elsevier.
- Hanai, T., Nishimura, K., Miwa, T., Maeda, T., Kenji, I., Atsushi, S., Koji, T., & Masahito, S. (2023). Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis. *JGH Open*, 73(3), 208–214.
- Hassan, M., & Moonka, D. (2018). Spontaneous bacterial peritonitis. *Liver Disease: A Clinical Case*, 2(1), 37–45.
- Higuera, D. L. T. F., Ponciano, G., Vargas, V. F., & Uribe, M. (2022). Hepatic

- encephalopathy in cirrhosis: Pathophysiology, diagnosis, and management. *World Journal of Hepatology*, *14*(2), 165–180.
- Jagdish, R. K., Roy, A., Kumar, K., Premkumar, M., Sharma, M., Rao, P. N., Reddy, D. N., & Kulkarni, A. V. (2023). Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. *Frontiers in Medicine*, *10*(5), 10–19.
- Jain, A., Singh, S., & Maiwall, R. (2025). Future management of sepsis in liver cirrhosis. *Journal of Clinical and Experimental Hepatology*, *16*(1), 103–194.
- Jepsen, P. (2014). Comorbidity in cirrhosis. *World Journal of Gastroenterology*, *20*(23), 7223–7230.
- Kementerian Kesehatan Republik Indonesia. (2013). *Riset Kesehatan Dasar (Riskesdas) 2013*. <https://layanandata.kemkes.go.id/katalog-data/riskesdas/ketersediaan-data/riskesdas-2013>
- Kementerian Kesehatan Republik Indonesia. (2023). *Survei Kesehatan Indonesia (SKI) 2023*. <https://www.badankebijakan.kemkes.go.id/hasil-ski-2023/>
- Khan, S., & Linganna, M. (2023). Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome. *Cleveland Clinic Journal of Medicine*, *90*(4), 209–213.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2020). *Robbins & Cotran pathologic basis of disease*. 10th Ed. Amsterdam: Elsevier.
- Lorensia, A., & Gorisalam, E. (2018). Analisis Masalah Terkait Obat Pengobatan Antidiabetes Pada Pasien Sirosis Hati Dengan Diabetes Mellitus Tipe 2 Di Suatu Rumah Sakit Di Surabaya. *Sains & Teknologi*, *9*(2), 58–73.
- Lovena, A., Miro, S., & Efrida, E. (2017). Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, *6*(1), 5–10.
- M Maghfirah, D., Abubakar, A., & Yusuf, F. (2018). Penatalaksanaan Asites pada Sirosis Hepatis. *Jurnal Kedokteran Nanggroe Medika*, *1*(3), 47–58.
- Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. *Expert Opinion on Drug Safety*, *13*(1), 57–65.
- McHugh, M. L. (2013). The Chi-square test of independence. *Biochemia Medica*, *23*(2), 143–149.
- Mulyo, S. (2016). Profilaksis Primer Perdarahan Varises Gastroesofagus pada Sirosis Hati : Peranan Penghambat Beta. *Jurnal CDK*, *43*(12), 940–944.
- Odriozola, A., Puente, Á., Cuadrado, A., Rivas, C., Anton, Á., González, F. J., Pellón, R., Fábrega, E., Crespo, J., & Fortea, J. I. (2022). Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. *Journal of Clinical Medicine*, *11*(21), 210–222.
- Rahmawati, L. A., & Hidayat, N. (2023). Sirosis Hepatis dengan Melena dan Ascites. *Continuing Medical Education*, *5*(2), 694–703.
- Ramadhan, M. G., Abidin, M. R. Z., & Wardani, E. (2024). Efektifitas Pemberian

- Betahistin pada Pasien Vertigo Usia 53 Tahun. *Jurnal Syntax Admiration*, 15(1), 37–48.
- Ramírez, M., & García, J. I. (2024). The multifaceted role of bilirubin in liver disease. *Journal of Clinical and Translational Hepatology*, 12(2), 1–10.
- Reau, N., & Brown, K. A. (2025). Liver lineup: Advances in portal hypertension and cirrhosis management. *HCPLive*, 3(2), 25–37.
- Rivera, H. ., Carrillo, R. J., & Martinez, S. (2025). Prevalence of polypharmacy in patients with a diagnosis of liver cirrhosis treated in the Gastroenterology service of the La Raza National Medical Center. *Annals of Hepatology*, 30(1), 101–812.
- Sarin, S. K., & Kumar, A. (2020). Acute variceal bleeding in cirrhosis: Current concepts. *Liver International. Hepatol International*, 40(2), 1021–1025.
- Schrier, R. W. (2010). *Diseases of the kidney and urinary tract* (9th Ed). Philadelphia: Lippincott Williams & Wilkins.
- Sherlock, S., & Dooley, J. (2018). *Diseases of the liver and biliary system*. 13th Ed. New Jersey: Wiley-Blackwell.
- Singh, J., Ebaid, M., & Saab, S. (2024). Advances in the management of complications from cirrhosis. *Gastroenterology Report*, 12(4), 20–28.
- Sulistyoningrum, E., & Murtisiwi, L. (2019). Description Of Preparation In Installation Of Panti diagnosis di Instalasi Rawat Jalan Rumah Sakit. *Journal of Pharmacy*, 9(1), 1–7.
- Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2021). Liver cirrhosis. *The Lancet*, 383(9930), 1749–1761.
- Usman, F. H., Birman, Y., & Wahyuni, S. (2025). Profil Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *HEME*, 7(2), 29–42.
- Virma, S. G., Adelin, P., & Mona, L. (2023). Karakteristik Pasien Sirosis Hepatis di Rumah Sakit Dr. Achmad Mochtar Bukittinggi. *Jurnal Kedokteran Nanggroe Medika*, 6(1), 1–8.
- Wang, X., & Wu, B. (2019). Critical issues in the diagnosis and treatment of liver cirrhosis. *Gastroenterology Report*, 7(4), 227–230.
- Wiranata, I. M., Hasmono, D., Surdijati, S., Farmasi, F., & Airlangga, U. (2017). Studi Penggunaan Omeprazole pada Pasien Sirosis Hati dengan Hemetamesis Melena Rawat Inap di RSUD Kabupaten Sidoarjo Fakultas Farmasi, Universitas Katolik Widya Mandala Surabaya, Indonesia The Study of Omeprazole in Cirrhosis Patients with Hematemesis Melena. *Journal of Pharmacy Science and Practice I*, 4(1), 36–43.
- Wong, F. (2024). Hepatorenal syndrome in cirrhosis : treatment and outcomes. *Gastroenterology*, 148(20), 150–159.
- World Health Organization. (2018). *Global status report on alcohol and health 2018*. <https://www.who.int/publications/i/item/9789241565639>

- World Health Organization. (2022). *Noncommunicable diseases*. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
- Yasin, Y., Bahrun, U., & Samad, I. A. (2015). Analisis Feritin Dan Ast To Platelet Ratio Index Sebagai Petanda Derajat Fibrosis Penyakit Hati Kronis. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 22(1), 72–76.
- Yuen, M. F., Chen, D. S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C. L. (2018). Hepatitis B virus infection. *Nature Reviews Disease Primers*, 4(5), 1–21.
- Zakiyya, N., Irwandi, I., Studi, P., Dokter, P., Kedokteran, F., Malikussaleh, U., Ilmu, B., Dalam, P., Sakit, R., Meutia, C., Utara, A., & Cunda, U. (2025). Case Report : Pasien Laki-Laki Usia 48 Tahun dengan Sirosis Hepatis Stadium Dekompensata Relatif Hepatitis B. *Vitalitas Medis*, 2(1), 20–28.
- Zhao, Y. (2024). Pulmonary Bacterial Infection and Liver Cirrhosis. *Immunology and Disease*, 3(1), 45–53.

